Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
AYTU 
Aytu BioScience Inc (AYTU)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: AYTU (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $9.67
1 Year Target Price $9.67
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -11.37% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 21.19M USD | Price to earnings Ratio - | 1Y Target Price 9.67 |
Price to earnings Ratio - | 1Y Target Price 9.67 | ||
Volume (30-day avg) 1 | Beta 0.23 | 52 Weeks Range 0.95 - 2.85 | Updated Date 09/14/2025 |
52 Weeks Range 0.95 - 2.85 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.49 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 2.01% | Operating Margin (TTM) 13.12% |
Management Effectiveness
Return on Assets (TTM) -0.59% | Return on Equity (TTM) -3.06% |
Valuation
Trailing PE - | Forward PE 3.69 | Enterprise Value 24432517 | Price to Sales(TTM) 0.26 |
Enterprise Value 24432517 | Price to Sales(TTM) 0.26 | ||
Enterprise Value to Revenue 0.3 | Enterprise Value to EBITDA 2.3 | Shares Outstanding 8976910 | Shares Floating 3913849 |
Shares Outstanding 8976910 | Shares Floating 3913849 | ||
Percent Insiders 7.58 | Percent Institutions 38.09 |
Upturn AI SWOT
Aytu BioScience Inc
Company Overview
History and Background
Aytu BioScience Inc., now known as VYERA Therapeutics, was founded with a focus on commercializing novel products in the field of urology and related therapeutic areas. It expanded through acquisitions and internal product development.
Core Business Areas
- Urology: Development and commercialization of products related to men's health and urological conditions, including treatments for erectile dysfunction.
Leadership and Structure
Information on leadership and organizational structure can be found on VYERA Therapeutics' website or through company filings, but unavailable without further information
Top Products and Market Share
Key Offerings
Market Dynamics
Industry Overview
The urology market is driven by the aging population, increasing prevalence of urological diseases, and advancements in treatment options.
Positioning
VYERA Therapeutics is positioned within the urology market, focusing on addressing unmet needs within specific therapeutic areas.
Total Addressable Market (TAM)
Specific TAM figures would require detailed market analysis, which is unavailable without more information.
Upturn SWOT Analysis
Strengths
Weaknesses
Opportunities
Threats
Competitors and Market Share
Key Competitors
Competitive Landscape
Analysis of competitive landscape unavailable without further information or access to specific financial reports.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is unavailable without further information or access to specific financial reports.
Future Projections: Future projections are unavailable without further information or access to specific financial reports.
Recent Initiatives: Recent strategic initiatives can be found in company press releases and investor presentations, but unavailable without further research.
Summary
Analysis of VYERA Therapeutics is currently difficult due to lack of available information. There is not enough information to provide a sound summarization. Without access to financial and market data, it's impossible to assess the company's strengths, weaknesses, and overall outlook.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Publicly available information.
Disclaimers:
The data provided is based on limited information and may not be comprehensive. This analysis is for informational purposes only and should not be considered financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aytu BioScience Inc
Exchange NASDAQ | Headquaters Denver, CO, United States | ||
IPO Launch date 2017-02-01 | CEO & Director Mr. Joshua R. Disbrow | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 102 | Website https://aytubio.com |
Full time employees 102 | Website https://aytubio.com | ||
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above, and Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.